tiprankstipranks
Trending News
More News >
Algernon Pharmaceuticals (TSE:AGN)
:AGN
Canadian Market

Algernon Pharmaceuticals (AGN) Income Statement

Compare
37 Followers

Algernon Pharmaceuticals Income Statement

Last quarter (Q4 2025), Algernon Pharmaceuticals's total revenue was C$0.00, a decrease of ― from the same quarter last year. In Q4, Algernon Pharmaceuticals's net income was C$-380.50K. See Algernon Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
C$ 0.00C$ 0.00C$ 0.00C$ 0.00C$ 0.00
Gross Profit
C$ -54.69KC$ -26.56KC$ -50.40KC$ -34.94KC$ 0.00
Operating Expenses
C$ 1.66MC$ 2.39MC$ 5.24MC$ 6.02MC$ 8.05M
Depreciation and Amortization
C$ 54.69KC$ 26.56KC$ 50.40KC$ 34.94KC$ -317.05K
EBITDA
C$ -1.66MC$ -476.42KC$ -4.98MC$ -6.02MC$ -8.05M
Operating Income
C$ -1.72MC$ -2.41MC$ -5.02MC$ -6.12MC$ -9.84M
Other Income/Expenses
C$ 739.00C$ 0.00C$ -1.76MC$ 63.27KC$ 2.11M
Pretax Income
C$ -1.72MC$ -502.98KC$ -6.78MC$ -6.05MC$ -7.73M
Net Income
C$ -1.72MC$ -502.98KC$ -6.78MC$ -6.05MC$ -7.73M
Per Share Metrics
Basic EPS
C$ -0.06C$ -0.03C$ -0.45C$ -0.87C$ -1.04
Diluted EPS
C$ -0.06C$ -0.03C$ -0.45C$ -0.87C$ -1.04
Weighted Average Shares Outstanding
29.49M 20.05M 15.15M 6.95M 7.44M
Weighted Average Shares Outstanding (Diluted)
29.49M 20.05M 15.15M 6.95M 7.44M
Currency in CAD

Algernon Pharmaceuticals Earnings and Revenue History